I- SCI, SSCI ve AHCI kapsamındaki uluslararası yayınlar

1. Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A. (2023). Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study. Medicine, 102(5).

2. Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A. (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), e31726.

3. Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran,

M. (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing’s sarcoma: A single institution experience. Medicine, 101(49), e32213.

4. Paksoy, Nail, et al. Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report. Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221.

5. Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A. (2022). Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine, 101(50), e32368.

6. Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A. (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34).

7. HAS SIMSEK, Duygu, et al. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. Annals of Nuclear Medicine, 2021, 35.6: 680-690.

8. TURAL, Deniz, et al. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences. European Urology Focus, 2021, 7.5: 1061-1066.

9. FERHATOGLU, Ferhat, et al. Clinicopathological and prognostic features of 67 cases with pulmonary sarcomatoid carcinoma: an 18-year single-centre experience. Oncology Research and Treatment, 2021, 44.11: 590-601.

10. TURAL, Deniz, et al. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. International Journal of Clinical Oncology, 2021, 26.8: 1506- 1513.

11. GÜRBÜZ, Mustafa, et al. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. Journal of Cancer Research and Clinical Oncology, 2022, 1-9.

12. AY, Seval, et al. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of Chemotherapy, 2022, 1-7.

13. CIL, Ibrahim, et al. Efficacy and safety of trastuzumab emtansine in older patients with HER2- positive advanced breast cancer: a real-world study. Tumori Journal, 2022, 108.1: 19-25.

14. HIZAL, Mutlu, et al. The real-life efficacy and safety of osimertinib in pretreated advanced non- small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508.

15. Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N. (2023). The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148.

16. Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A.

N. (2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced- stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncology, 18(23), 2573-2582.

17. Dogan, I., Karabulut, S., Tastekin, D., Ferhatoglu, F., Paksoy, N., & Sakar, B. (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. J Coll Physicians Surg Pak, 32, 1014-1019.

18. DEMIR, Semra, et al. A practical 16-day desensitization protocol in lenalidomide-induced non- immediate hypersensitivity reactions. Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397.

19. ÖZDEMIR, Seçil Kepil, et al. Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors. Allergy, 2019, 74.6: 1187-1190.

20. Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S. (2023). Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. The Oncologist, oyad257.

21. Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ. (2023). Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC cancer, 23(1), 192.

22. Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A. (2023). Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression. Scientific Reports, 13(1), 8779.

23. Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A. (2023). Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients. Journal of Cancer Research and Clinical Oncology, 1-9.

24. Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A. (2023). Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine. European Journal of Breast Health, 19(2), 128.

25. Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur,

M. A. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor- positive/HER2-negative metastatic breast cancer. Future Oncology, 19(10), 727-736.

26. Dogan, I., Paksoy, N., & Basaran, M. (2023). Efficacy and safety of sorafenib in adult metastatic osteosarcoma patients. Journal of Cancer Research and Therapeutics.

27. Dogan, I., Paksoy, N., & Basaran, M. (2023). Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients. Journal of Cancer Research and Therapeutics.

28. Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M. (2023). Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases. Journal of Cancer Research and Therapeutics.

29. Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S. (2022). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience. Journal of Cancer Research and Therapeutics.

30. Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N. (2022). Prognostic factors of perioperative FLOT regimen in operable gastric and.

31. Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A. (2023). Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center. Medicine, 102(39), e35383.

32. Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M. (2023). Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience. Medicine, 102(41), e35245.

II-Diğer uluslararası yayınlar

1- PAKSOY, N., FERHATOĞLU, F., DOĞAN, İ., KHANMAMMADOV, N., BOZBEY, H. U.,

KARABULUT, S., & TAŞTEKİN, D. (2022). Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study. TURKISH JOURNAL OF ONCOLOGY, 1(1).

2- PAKSOY, N., TRABULUS, S., SEYAHİ, N., & ALTIPARMAK, M. R. (2023). Demographic and

Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience. Namik Kemal Tip Dergisi, 11(1).

3- PAKSOY, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2022). Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors.

4- AK, Naziye, et al. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer. Journal of oncological sciences, 2021, 7.2: 42-49.

5- AK, Naziye, et al. Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4.

6- Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D. (2022). Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib.

7- Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine,

A. (2022). Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY.

8- Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology.

9- Ferhatoglu, F., Cagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. (2023). Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study. Eurasian Journal of Medical Investigation, 7(2).

10- FERHATOĞLU, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. (2023). Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital. Turk Onkoloji Dergisi, 38(1).

11- FERHATOĞLU, F., PAKSOY, N., & BAŞARAN, M. (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namik Kemal Tip Dergisi, 10(4).

12- Ferhatoglu, F., Aydiner, A., & Paksoy, N. (2022). Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer. Journal of Surgery & Medicine (JOSAM), 6(12).

13- Unal, C., Selcuk, N. A., Biricik, F. S., Alan, O., Ordu, C., Selvi, O., ... & Saglam, S. (2023). Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye.

ULUSLARARASI KONGRE SÖZLÜ BİLDİRİ ÖZETLERİ

1- Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022). Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.

2- Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022). Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study.

3- Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021). Long- term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

4- Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021). Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

5- Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021).

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

6- Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021). Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.

7- Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021). Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.

8- Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021). Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

9- Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023). Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.

10- Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021). Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first- line chemotherapy: results of real-life experiences. European urology focus, 7(5), 1061-1066.

ULUSLARARASI SUNUM:

1- ESMO Preceptorship Neuro Oncology Meeting, 23-24 June 2022, Brain Tumour, Session 6: Leptomeningial Carsinomatosis,

Lugano/SWİTZERLAND

KİTAP YAZARLIĞI

1- Oncological Emergencies, Chapter: 19, Side Effect Of Immunotherapy, ISBN: 978- 625-7409-99-5, 2021

2- Multidisciplinary Approach To Thyroid Diesease, Chapter: 37, Anaplastic Thyroid Carcinoma, 2021, ISBN: 978-625-7409-53-7, 2021

3- Supportive Care And Symptoms Management In Cancer, Chapter: 16, Management Of Constipation In Oncology Patients, ISBN: 978-625-7401-53-1, 2021

4- Geriatrics Textbook, Elderly Health and Diseases, Chapter: 27, Cancer, ISBN: 978- 625-7399-03-6, 2021

5- Türkiye Clinics Journal of Medical Sciences (Special issue) Gastroesophageal Junctıon Cancer. Chapter; Neoadjuvant and adjuvant Therapies in the Treatment of Gastroesophageal Junction Cancer, ISBN: 978-625-401-787-2, 2022

6- Türkiye Clinics Journal of Medical Sciences (Special issue) Heredıtary Gynecologıcal Cancers-The Role Of Molecular Pathology In Prognosıs And Treatment. Chapter; The Role of Immunotherapy in Ovarian Cancer Treatment, ISBN: 978-625-401-840-4, 2022

7- Rare Tumors, Chapter: 37, Merkel Cell Carcınoma, ISBN: 978-625-8259-58-2, 2022

8- Paraneoplastic Syndromes, Chapter 16, Tumor-induced osteomalacia, SBN: 978-625-

7679-66-4, 2022

ULUSLARARASI KLINIK ARAŞTIRMA PROJELERİ

1. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High

Risk of Recurrence Following Preoperative Therapy (Astefania) – ROCHE – SUBINVESTIGATOR

2. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC – PFİZER – SUBINVESTIGATOR

3. Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE) – AMGEN – SUBINVESTIGATOR

4. A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) – BAYER – SUBINVESTIGATOR

5. A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) – Tesaro (PRA) – SUBINVESTIGATOR

6. Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non- mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK- 001/ENGOT-ov43/GOG-3036) – MSD – SUBINVESTOGATOR

7. To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. – ASTRA ZENECA – SUBINVESTIGATOR

8. Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)- ASTRA ZENECA – SUBINVESTIGATOR

Assoc. Prof. Nai̇l PAKSOY, M.D.